Viewing Study NCT05665595

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 1:49 PM

Ignite Modification Date: 2025-12-27 @ 10:18 PM

Study NCT ID: NCT05665595

Status: COMPLETED

Last Update Posted: 2025-10-15

First Post: 2022-12-16

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Sponsor: Merck Sharp & Dohme LLC

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module Adverse Events Module Baseline Characteristics Module Participant Flow Module